New Drug Approved to Treat ADHD

The new drug Vyvanse received approval on Monday by the Food and Drug Administration to affectively treat Attention Deficit Hyperactivity Disorder. Although the medication received approval, it will come with a black box warning due to the possible side affects of the amphetamine contained in the medication.

The drug is manufactured by Shire PLC, the manufacturer of the current blockbuster ADHD medication Aderall XR. According to HealthDay, “The wire service quotes Shire spokesman Matt Cabrey as saying that the company has tested Vyvanse on adults who have a history of stimulant abuse to assess its “likeability.” The outcome, according to Shire, was that Vyvanse delays the intensity of amphetamine effects, which include increased alertness, physical activity, and decreased appetite.”

The ADHD drug is being produced by Shire PLC in hopes to replace Aderall XR who patent expires in 2009. According to IMS Health, Total sales for Aderall have increased by more than 300 percent in the last four years, earning more than $3.6 billion last year.

According to a recent poll from the US Department of Education, one in every ten students of 22 million students polled said they used or have used Aderall or a similar medication, many without a prescription. Many college students report using Aderall to pull all nighters, or cram for an upcoming test.

ADHD medication increased concentration, alertness, focus, short term memory, and wakefulness. Some side affects include suppressed appetite, amphetamine dependency, and heart attack.

Visit this Consumer Advocacy website for more information on ordering from an online Mexican pharmacy.